🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome

Recruitingn/aAges 18 Years - 80 YearsAllFirst Affiliated Hospital of Fujian Medical Unive…
NCT07547098 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older. * Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage. * Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping. * Willingness to participate and provision of written informed consent. * Ability to complete baseline assessment and follow-up. * Full civil capacity and ability to understand study information. Exclusion Criteria: * Refusal to provide written informed consent. * Severe psychiatric disease or cognitive impairment precluding participation. * End-stage disease with expected survival less than 1 year. * Long-term absence more than 6 months preventing reliable follow-up. * Participation in another clinical study that may interfere with endpoint adjudication. * Missing key fields preventing linkage of examinations, imaging, and outcomes.
💊

What it tests

  • Not listed
📍

Where

1 site
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy